Jose B Martinez V.

Médico internista y Reumatólogo
Universidad Nacional de Colombia

[Dr. John Cush @RheumNow]

Gout and its' associated comorbidities - treat gout and its' comorbidities to target

https://t.co/U0dolcAGEc

[Dr. John Cush @RheumNow]

MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/jE9xwSl6Y2

[Aravind Palraj @Rheumat_Aravind]

FEVER + RASH + ARTHRITIS

One of the most important diagnostic patterns in medicine.

When these three features occur together, the differential diagnosis extends far beyond rheumatology and includes infection, systemic inflammatory disease, autoimmunity, and post-infectious syndromes.

Key diagnoses you should never miss:
• Adult-onset Still disease / Systemic JIA
• SLE
• Reactive arthritis
• Viral arthritis
• Disseminated gonococcal infection
• Behçet disease
• Infective endocarditis
• Acute rheumatic fever

Before ordering a large autoimmune panel, ask yourself:

Which diagnosis would I regret missing today?

What would be your first differential when faced with a patient presenting with fever, rash, and arthritis?

Infographic by Dr. Aravind Palraj

#Rheumatology #InternalMedicine #MedicalEducation #MedEd #FOAMed #ClinicalReasoning #DifferentialDiagnosis #AutoimmuneDisease #MedTwitter #RheumTwitter #InfectiousDiseases #MedX #MedicalStudents #Residency #Medicine @IhabFathiSulima @docakx

[Jose B Martinez V. @jmartinezv2003]

@Rincon001A Es lamentable que periodistas como Néstor y Luis Ernesto no sean objetivos, y se expresen más como resentidos por la brillante respuesta que hizo Abelardo, a preguntas "necias", respuestas contundentes. Ahí que prepararse para preguntar a personas con la habilidad del Tigre

[The Lancet Rheumatology @TheLancetRheum]

NEW RESEARCH—Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study https://t.co/gJ6thUjsM3

[Dr. John Cush @RheumNow]

FDA vs. Amgen: At Odds Over Avacopan

The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market.

https://t.co/5EU2lgX6XX

[RMD Open @bmj_rmdopen]

🧬 Multi-omics research stratifies 144 axial spondyloarthritis patients using transcriptomics and proteomics to predict radiographic progression over 5 years

📊 Two genes (KAT2B & EMP3) combined with baseline spinal damage scores effectively predicted moderate-to-fast radiographic progressors

💡 Molecular profiling could enable personalized treatment by identifying high-risk axSpA patients before irreversible structural damage occurs

https://t.co/Y3FB0QsOzy

[Eric Dein @ericdeinmd]

Update of 2025 ASAS-SPARTAN Revised Classification Criteria for AxSpA
@RheumNow #RNL26
Notes must exclude mimics
MRI findings involve active & structural lesions, not just bone marrow edema
Difficult to meet clinically without any imaging criteria (xray or MRI)
Pub pending

[Richard Conway @RichardPAConway]

ACR/Chest and EULAR/ERS guidelines for RA-ILD presented by Dr Sparks. I'm posting the one I use ;) #RNL26 @RheumNow

[Jose B Martinez V. @jmartinezv2003]

@WilsonBautistaM @NatRevRheumatol @Nature Felicitaciones amigo, merecido reconocimiento, me uno a tu felicidad, un abrazo 🤗🤗

[Dr. John Cush @RheumNow]

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and prevent autoimmune disease.

https://t.co/xqLnlWDq8c

[Jose B Martinez V. @jmartinezv2003]

https://t.co/KG9kHB9l3w

[Dr. John Cush @RheumNow]

Inception SLE study of 674 pts (without LN), mean age 34 yrs - 154 (23%) developed new proteinuria (LN) after median of 3.6 yr. Cumulative antimalarial exposure did NOT lower risk of LN (HR 0.98; 0.94-1.02); same for those w/ serologically active SLE (HR 0.97) https://t.co/uu75wzyzfw

[Dr. John Cush @RheumNow]

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia

Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months.

https://t.co/HLLhwgcVrS

[Luis Rincón Arguello 🇨🇴 @Rincon001A]

Cuanta razón tenia Luis Carlos Galán

[Asoreuma @Asoreuma]

⚠️ Reiteramos nuestro llamado a todos nuestros pacientes:
Si tienes una enfermedad reumática y estás en tratamiento inmunosupresor, NO debes aplicarte la vacuna contra la fiebre amarilla sin consultar primero con tu reumatólogo tratante.

[Dr. John Cush @RheumNow]

Metanalysis suggests MTX may be effective in knee OA. 6RCTs, 602 pts of MTX vs PBO, showed MTX significantly relieved pain (mean diff −0.44; P 0.0003) knee/hand OA; Functional improved for knee only, but no differences in quality-of-life outcome or adverse events https://t.co/pZ1UyJxGjp

[ClinRheumatol @ClinRheumatol]

Late-Onset #AxSpA (lo-axSpA): A Distinct Subgroup?
👉https://t.co/Q4uBTTG1KL
📊 Key findings from the Reuma-check cohort:
✔️ 28% of axSpA cases started at ≥45 years.
✔️ More common in females (51%) & psoriasis (42%).
✔️ Lower NSAID response (52%) & HLA-B27 positivity (32%).
✔️ Shorter diagnosis delay (40 vs. 93 months) than early-onset axSpA
⚠️ lo-axSpA may require distinct diagnostic & treatment approaches.
https://t.co/doS6Y5oVy2

[Ronny Suárez Celemín @RonnySuarez_]

La Asociación Colombiana de Reumatología @Asoreuma expresa su preocupación por los problemas de acceso a medicamentos que están teniendo pacientes de enfermedades como artritis reumatoide, lupus eritematoso sistémico, vasculitis y esclerosis sistémica. Piden acciones urgentes👇

[Jose B Martinez V. @jmartinezv2003]

https://t.co/bInw7j9pai